Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
“COVID-19 antigen testing
The Company has made recent progress in relation to two projects involving scale-up and technical transfer to manufacture. Avacta plc's AffiDX® SARS-CoV-2 antigen lateral flow test is being validated to allow commercial product to be manufactured and released by Abingdon Health. Avacta have indicated that they may require the Company to produce between one and two million tests per month. The transfer process, which involves scale-up of processes and manufacture of three production-scale manufacturing runs, is progressing well and due for completion in this calendar year. A significant order for post-technical transfer production has been received from Avacta.”
Oh…. Hello
Thanks Mr R,
Dare we say now then, and finally, that the ABDX manufax capacity will be online - imminently?
Well it says it right there. We’re within weeks of year end and they’ve already received a significant order from Avacta.
Nice to hear it second hand, good to see AS keeping up investor relations.
nice, so 3 weeks ish we have second manufacturer online.
would hope HUA and Desktop review will also be completed this year.
Happy Christmas, HO HO HO!!
So Potentially 1-2m per month but a significant order already received.
So you’d assume either HUA is imminent or they’ve received a large professional use order. I’d guess it’s HUA. Which brings the Medusa Stocking filler into play this Christmas. But either way it’s good to know that TT is finally in its last few weeks.
This obviously means some thing significant for Abingdon. That Al doesn’t release news either means it’s not nailed on, or diagnostics is not worth the bother, and he doesn’t think the SP is going to affected. Not sure which option I prefer
It’s good news morning, happy head on.
Nice, very nice!
It has taken far longer than anyone imagined but capacity is ramping up in the background and is DEMAND DRIVEN, per guidance from AS.
Clearly, as is evident with this new variant, Covid is far from behind us... In fact, unless the entire world vacinates to deliver herd immunity (which is years and years away, perhaps never possible) a decent demand for high quality tests will be around forever! Cha ching for avct. Patience will be rewarded here.
Avct have announced this, its not new news
Manufacturing process has been transferred to Abingdon Health and the validation batches
are now entering production.
• Abingdon Health could add a further 1-2 million tests per month capacity
https://avacta.com/wp-content/uploads/2021/09/Avacta-Group-plc-Interim-Results-Final.pdf
Yep
The whole ABDX placing RNS is worth a gander.
Its working capital priorities are the scaling up of manufacture for Avacta and Vatic.
Interestingly (to me) however no details are given of the progress of the Vatic TT.
I’m just glad I bought a bit of research to the board for once instead of just calling people twats. RD will be proud.
Still not quite there but finally now within touching distance.
Get these made. Get em sold and at a profit margin that makes the last 18 months worthwhile and finally Avacta (and it's SP) will gather the momentum (based on actual revenues and products rather than soundbytes) that we have all been waiting for.
After 18 months of being on the percieved cusp, the ACTUAL cusp is here.
Good luck all.
Mr ripley thank you very much for that info.
Along with the news regarding America rubbing stamping the AVA tests things are really really starting to look very nice indeed
Kong
Do you have a link MrR?
Don’t bite….
It’s in the ABDX RNS Losta
NDN…. Ssssshhhh. You’re embarrassing yourself again.
1-2m tests a month from Abingdon isnt too shabby, Ndn.
Haha Bein. I can’t be arsed with him. Binned.
ndn - I'm not complaining: 'Avacta have indicated that they may require the Company to produce between one and two million tests per month. The transfer process, which involves scale-up of processes and manufacture of three production-scale manufacturing runs, is progressing well and due for completion in this calendar year. A significant order for post-technical transfer production has been received from Avacta.'
Ndn hates good news.
This is a Pinocchio moment for you now, Mr R; you’re now a ‘real researcher’. Haha.
Thanks MrR, excellent news.
Good work Mr R
I am confused:
Currently AVCT have 1m per month production capacity with GAD. (Is that correct?)
I have assumed that it is nor running to capacity only because at £1 profit per test that would be a meaningful income and would warrant an update I would have thought?
So if there is a sizeable order that is just been sitting there waiting to be fulfilled then why hasn't GAD done it? Why are we waiting for ABDX?
Why hasn't Medusa done it either?
So if we are making £12m per year pro rate (a multiple of annual earnings) then why hasn't AVCT told the market?
Does it make sense to anyone here?
I'm not doubting anything, I just don't understand the logistics.
"A significant order for post-technical transfer production has been received from Avacta.”
So what are we waiting for? Is that order conditional on something? (Why would we give to abdx if they are not in a position yet hand have not been for months, to fulfill it?)
Are we running at full capacity elsewhere and that order will just sit there for another month?
My take
How narcissistic do you have to be to keep coming here day after day when nobody gives a hook what you think…..